位置:首页 > 产品库 > Nizatidine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Nizatidine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Nizatidine图片
CAS NO:76963-41-2
规格:≥98%
包装与价格:
包装价格(元)
1g询价
2g询价
5g询价
10g询价
25g询价

理化性质和储存条件
Molecular Weight (MW)331.46
FormulaC12H21N5O2S2
CAS No.76963-41-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 66 mg/mL (199.1 mM)
Water: 28 mg/mL (84.5 mM)
Ethanol: 18 mg/mL (54.3 mM)
Solubility (In vivo)Saline: 30 mg/mL
SynonymsLY 139037, Tazac, Axid, LY-139037, LY139037
实验参考方法
In Vitro

In vitro activity: Nizatidine, a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion, with IC50 of 0.9 NM. Nizatidine also reversibly inhibits acetylcholinesterase (AChE), with IC50 of 6.7 μM, and the inhibition is noncompetitive, with a Ki value of 7.4 μM.


Kinase Assay: Nizatidine, a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion, with IC50 of 0.9 nM. Nizatidine exhibits maximal inhibition of gastric acid in rats within the first hour of drug administration, with EC50 of 1.383 μmol/kg. Nizatidine also reversibly inhibits acetylcholinesterase (AChE), with IC50 of 6.7 μM, and the inhibition is noncompetitive, with a Ki value of 7.4 μM. Nizatidine (0.3-3 mg/kg, i.v.) significantly increases the motor index of gastrointestinal (GI) motility in a dose-dependent manner. Nizatidine inhibits gastric acid secretion with ED50 and ED90 of 0.18 and 3.22 mg/kg in dogs, and 2.94 and 19.6 mg/kg in rats, respectively.

In VivoNizatidine exhibits maximal inhibition of gastric acid in rats within the first hour of drug administration, with EC50 of 1.383 μmol/kg. Nizatidine (0.3-3 mg/kg, i.v.) significantly increases the motor index of gastrointestinal (GI) motility in a dose-dependent manner. Nizatidine inhibits gastric acid secretion with ED50 and ED90 of 0.18 and 3.22 mg/kg in dogs, and 2.94 and 19.6 mg/kg in rats, respectively.
Animal modelRat
Formulation & DosageDissolved in saline; 0.5-10 μmol/kg; s.c. injection
References

J Pharmacol Exp Ther. 1986 Nov;239(2):406-10; J Pharmacol Exp Ther. 1993 Jan;264(1):152-7.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024